Predict your next investment

Corporation
mhtx.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

2

Partners & Customers

6

About Manhattan Scientifics

Manhattan Scientifics is located in New Mexico, New York, and Montreal. The company's goal is to advance and commercialize disruptive technologies to create profit for its shareholders. It is focused on commercializing disruptive technology in the fields of nanotechnology and nanomedicine.

Manhattan Scientifics Headquarters Location

405 Lexington Avenue The Chrysler Building 26th Floor

New York, New York, 10174,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Manhattan Scientifics News

Manhattan Scientifics Announces Early Results from Cancer Company

Mar 17, 2022

March 17, 2022 08:41 AM Eastern Daylight Time NEW YORK--( BUSINESS WIRE )--Manhattan Scientifics Inc. ( OTCQB: MHTX ), announces positive early results from Imagion Biosystems Cancer Diagnostic human study. Imagion Biosystems Ltd. ( IBX.AX ) shares were up 46% trading 71 million shares. Manhattan Scientifics Inc., initially funded and is the current owner of more that 50 million shares of Imagion Biosystems Ltd. About Manhattan Scientifics, Inc. Manhattan Scientifics Inc. ( www.mhtx.com ) is focused on technology transfer and commercialization of transformative technologies. It has assisted incubating and financing four IPO’s working closely with Science Teams at the Los Alamos National Laboratory and the Sandia National Laboratory in New Mexico About Imagion Biosystems Imagion Biosystems ( www.imagionbiosystems.com )is developing a new non-radioactive and super-sensitive diagnostic imaging technology for very early detection of cancers. Imagion is listed on the Australian Stock Exchange ( ASX ). Forward-looking statement This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. Contacts

Manhattan Scientifics Investments

1 Investments

Manhattan Scientifics has made 1 investments. Their latest investment was in Novint Technologies as part of their Other Investors on .

CBI Logo

Manhattan Scientifics Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

Other Investors

Novint Technologies

Yes

Date

Round

Other Investors

Company

Novint Technologies

Amount

New?

Yes

Co-Investors

Sources

Manhattan Scientifics Portfolio Exits

2 Portfolio Exits

Manhattan Scientifics has 2 portfolio exits. Their latest portfolio exit was Imagion Biosystems on June 22, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/22/2017

IPO

$99M

Public

1

11/29/2016

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/22/2017

11/29/2016

Exit

IPO

Spinoff / Spinout

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

1

10

Manhattan Scientifics Acquisitions

2 Acquisitions

Manhattan Scientifics acquired 2 companies. Their latest acquisition was Imagion Biosystems on June 15, 2011.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/15/2011

$99M

Acquired

6/13/2011

Subscribe to see more

$99M

Subscribe to see more

0

Date

6/15/2011

6/13/2011

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Sources

0

Manhattan Scientifics Partners & Customers

6 Partners and customers

Manhattan Scientifics has 6 strategic partners and customers. Manhattan Scientifics recently partnered with General Cable on July 7, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

7/25/2016

Partner

United States

Joint Partnership to Develop Nano-structured Aluminum Conductor. Manhattan Scientifics Signs Development Agreement with General Cable.

NEW YORK -- Manhattan Scientifics , Inc. announced today that it has signed a $ 500,000 Joint Development Agreement with General Cable .

1

7/25/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

11/12/2008

Partner

United States

Subscribe to see more

Subscribe to see more

10

7/8/2008

Partner

United States

Subscribe to see more

Subscribe to see more

10

3/18/2008

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

7/25/2016

7/25/2016

11/12/2008

7/8/2008

3/18/2008

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Joint Partnership to Develop Nano-structured Aluminum Conductor. Manhattan Scientifics Signs Development Agreement with General Cable.

NEW YORK -- Manhattan Scientifics , Inc. announced today that it has signed a $ 500,000 Joint Development Agreement with General Cable .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.